{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:56Z","timestamp":1793134136357,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To develop a novel simulation model for ductal carcinoma in situ (DCIS), fully validate it, and provide new estimates for DCIS in the setting of population-based biennial screening.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A micro-simulation Markov model for DCIS (SimDCIS) was developed. Input parameters were independently derived from the literature and transition parameters were age- and grade-dependent. The model was applied to the Dutch biennial screening program. SimDCIS was internally, cross, and externally validated by comparison of the model output to data from the Netherlands Cancer Registry, a modelling study on the United Kingdom Frequency Trial, and the United Kingdom screening program, respectively. Univariate and probabilistic sensitivity analyses were performed to estimate uncertainty. DCIS regression, progression to invasive breast cancer (IBC), clinical detection, and screen-detection were estimated in Dutch screening setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SimDCIS matched observed data in internal, external, and cross-validation. The model was most sensitive to DCIS onset probability, and the maximum variation in screen-detection rate was 11%. In Dutch screening setting, DCIS regression, progression to IBC, clinical detection, and screen-detection were estimated at 8% (0\u201314%), 19% (16\u201324%), 8% (0\u201313%), and 61% (56\u201365%), respectively. Grade distribution was 20% grade 1, 38% grade 2, and 42% grade 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SimDCIS provides strong accuracy across validation methods and is particularly sensitive to DCIS onset probability. Most DCIS will be found through screening, of which less than 50% of DCIS will be grade 3, less than 1 in 10 will regress, and 1 out of 5 DCIS will progress to IBC in biennial screening setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10549-025-07639-0","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T03:40:15Z","timestamp":1740800415000},"page":"223-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The natural history of ductal carcinoma in situ: development, validation, and estimated outcomes of the SimDCIS model"],"prefix":"10.1007","volume":"211","author":[{"given":"Keris","family":"Poelhekken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique D.","family":"Dorrius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Dibden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"van der Vegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel J. W.","family":"Greuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"7639_CR1","doi-asserted-by":"crossref","unstructured":"B. Lauby-Secretan et al., \u2018Breast-Cancer Screening-Viewpoint of the IARC Working Group\u2019, 2015. [Online]. Available: http:\/\/handbooks.iarc.fr","DOI":"10.1056\/NEJMsr1504363"},{"issue":"3","key":"7639_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"7639_CR3","doi-asserted-by":"publisher","unstructured":"L. J. Grimm, H. Rahbar, M. Abdelmalak, A. H. Hall, and M. D. Ryser, (2022) \u2018Ductal Carcinoma in Situ: State-of-the-Art Review\u2019, Radiological Society of North America Inc. https:\/\/doi.org\/10.1148\/radiol.211839.","DOI":"10.1148\/radiol.211839"},{"key":"7639_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/0969141320945736","author":"H Weedon-Fekj\u00e6r","year":"2020","unstructured":"Weedon-Fekj\u00e6r H, Li X, Lee S (2020) Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data. J Med Screen. https:\/\/doi.org\/10.1177\/0969141320945736","journal-title":"J Med Screen"},{"key":"7639_CR5","unstructured":"IKNL, \u2018NKR cijfers borstkanker\u2019\u2019, iknl.nl\/nkr-cijfers."},{"key":"7639_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.07.012","author":"K Poelhekken","year":"2023","unstructured":"Poelhekken K, Lin Y, Greuter MJW, van der Vegt B, Dorrius M, de Bock GH (2023) The natural history of ductal carcinoma in situ (DCIS) in simulation models: A systematic review. Breast. https:\/\/doi.org\/10.1016\/j.breast.2023.07.012","journal-title":"Breast"},{"key":"7639_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0705-5","author":"PA van Luijt","year":"2016","unstructured":"van Luijt PA et al (2016) The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-016-0705-5","journal-title":"Breast Cancer Res"},{"key":"7639_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2016.12.030","volume":"75","author":"D Puliti","year":"2017","unstructured":"Puliti D et al (2017) Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy. Eur J Cancer 75:109\u2013116. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.030","journal-title":"Eur J Cancer"},{"key":"7639_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.027","volume":"173","author":"L Ding","year":"2022","unstructured":"Ding L et al (2022) Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective. Eur J Cancer 173:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.027","journal-title":"Eur J Cancer"},{"key":"7639_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030912","author":"R Strandberg","year":"2023","unstructured":"Strandberg R, Abrahamsson L, Isheden G, Humphreys K (2023) Tumour growth models of breast cancer for evaluating early detection\u2014a summary and a simulation study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030912","journal-title":"Cancers (Basel)"},{"key":"7639_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023187","author":"C Forastero","year":"2019","unstructured":"Forastero C, Zamora LI, Guirado D, Lallena AM (2019) Evaluation of the overdiagnosis in breast screening programmes using a Monte Carlo simulation tool: A study of the influence of the parameters defining the programme configuration. BMJ Open. https:\/\/doi.org\/10.1136\/bmjopen-2018-023187","journal-title":"BMJ Open"},{"key":"7639_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv372","author":"MD Ryser","year":"2016","unstructured":"Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES (2016) Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv372","journal-title":"J Natl Cancer Inst"},{"key":"7639_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3365","author":"NB Gunsoy","year":"2012","unstructured":"Gunsoy NB, Garcia-Closas M, Moss SM (2012) Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res. https:\/\/doi.org\/10.1186\/bcr3365","journal-title":"Breast Cancer Res"},{"key":"7639_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7017","author":"A Seigneurin","year":"2012","unstructured":"Seigneurin A, O. Franco\u0327is, J. Labar\u00e8re, P. Oudeville, J. Monlong, and M. Colonna, (2012) Overdiagnosis from non-progressive cancer detected by screening mammography: Stochastic simulation study with calibration to population based registry data. BMJ. https:\/\/doi.org\/10.1136\/bmj.d7017","journal-title":"BMJ"},{"issue":"3","key":"7639_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ypmed.2011.06.009","volume":"53","author":"R de Gelder","year":"2011","unstructured":"de Gelder R et al (2011) Digital mammography screening: Weighing reduced mortality against increased overdiagnosis. Prev Med (Baltim) 53(3):134\u2013140. https:\/\/doi.org\/10.1016\/j.ypmed.2011.06.009","journal-title":"Prev Med (Baltim)"},{"key":"7639_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01287-6","author":"S Chootipongchaivat","year":"2020","unstructured":"Chootipongchaivat S et al (2020) Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-020-01287-6","journal-title":"Breast Cancer Res"},{"key":"7639_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7773","author":"JL Carter","year":"2015","unstructured":"Carter JL, Coletti RJ, Harris RP (2015) Quantifying and monitoring overdiagnosis in cancer screening: A systematic review of methods. BMJ. https:\/\/doi.org\/10.1136\/bmj.g7773","journal-title":"BMJ"},{"issue":"5","key":"7639_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB (2012) Model transparency and validation: A report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 32(5):733\u2013743. https:\/\/doi.org\/10.1177\/0272989X12454579","journal-title":"Med Decis Making"},{"key":"7639_CR19","unstructured":"CBS, \u2018StatLine: Nederland in cijfers\u2019, https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/."},{"key":"7639_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30105","author":"N Segnan","year":"2016","unstructured":"Segnan N et al (2016) Epidemiologic evidence of slow growing, non-progressive or regressive breast cancer: A systematic review. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.30105","journal-title":"Int J Cancer"},{"issue":"9","key":"7639_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/JNCI\/DJY220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser MD et al (2019) Cancer outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst 111(9):952\u2013960. https:\/\/doi.org\/10.1093\/JNCI\/DJY220","journal-title":"J Natl Cancer Inst"},{"key":"7639_CR22","unstructured":"RIVM, \u2018Achtergrond Bevolkingsonderzoek borstkanker\u2019\u2019, https:\/\/www.rivm.nl\/bevolkingsonderzoek-borstkanker\/professionals\/achtergrond ."},{"key":"7639_CR23","unstructured":"IKNL, \u2018Monitor bevolkingsonderzoek borstkanker 2020\u20132021\u2019, 2021. https:\/\/iknl.nl\/kankersoorten\/borstkanker\/onderzoek\/monitor-bevolkingsonderzoek"},{"issue":"20","key":"7639_CR24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","volume":"94","author":"VL Ernster","year":"2002","unstructured":"Ernster VL et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546.\u00a0https:\/\/doi.org\/10.1093\/jnci\/94.20.1546","journal-title":"J Natl Cancer Inst"},{"key":"7639_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.clinimag.2020.11.050","volume":"73","author":"SL Venkatesh","year":"2021","unstructured":"Venkatesh SL, Oseni TO, Bahl M (2021) Symptomatic ductal carcinoma in situ (DCIS): Upstaging risk and predictors. Clin Imaging 73:101\u2013107. https:\/\/doi.org\/10.1016\/j.clinimag.2020.11.050","journal-title":"Clin Imaging"},{"key":"7639_CR26","unstructured":"NHS, \u2018Breast Screening Programme, England 2019\u201320\u2019. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/breast-screening-programme."},{"key":"7639_CR27","unstructured":"Statista, \u2018Age-specific death rate per 1,000 population in the United Kingdom in 2021 by gender\u2019. https:\/\/www.statista.com\/statistics\/1125118\/death-rate-united-kingdom-uk-by-age\/."},{"issue":"7","key":"7639_CR28","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/bjc.2011.300","volume":"105","author":"NT Van Ravesteyn","year":"2011","unstructured":"Van Ravesteyn NT, Heijnsdijk EAM, Draisma G, De Koning HJ (2011) Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: A model-based approach on screening intervals. Br J Cancer 105(7):1082\u20131088. https:\/\/doi.org\/10.1038\/bjc.2011.300","journal-title":"Br J Cancer"},{"issue":"11","key":"7639_CR29","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","volume":"38","author":"R Gidwani","year":"2020","unstructured":"Gidwani R, Russell LB (2020) Estimating transition probabilities from published evidence: a tutorial for decision modelers. Pharmacoeconomics 38(11):1153\u20131164. https:\/\/doi.org\/10.1007\/s40273-020-00937-z","journal-title":"Pharmacoeconomics"},{"key":"7639_CR30","unstructured":"U. of Oxford, \u2018AgeX Trial\u2019, University of Oxford. [Online]. Available: https:\/\/www.ceu.ox.ac.uk\/research\/agex-trial."},{"key":"7639_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01682-9","author":"T Heggland","year":"2023","unstructured":"Heggland T, Vatten LJ, Opdahl S, Weedon-Fekj\u00e6r H (2023) Non-progressive breast carcinomas detected at mammography screening: a population study. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-023-01682-9","journal-title":"Breast Cancer Res"},{"key":"7639_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00512-y","author":"AK Casasent","year":"2022","unstructured":"Casasent AK et al (2022) Learning to distinguish progressive and non-progressive ductal carcinoma in situ. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-022-00512-y","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7639_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-017-4412-4","volume":"166","author":"JD Luiten","year":"2017","unstructured":"Luiten JD, Voogd AC, Luiten EJT, Duijm LEM (2017) Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res Treat 166(1):307\u2013314. https:\/\/doi.org\/10.1007\/s10549-017-4412-4","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7639_CR34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1470-2045(15)00446-5","volume":"17","author":"SW Duffy","year":"2016","unstructured":"Duffy SW et al (2016) Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: A retrospective population-based study. Lancet Oncol 17(1):109\u2013114. https:\/\/doi.org\/10.1016\/S1470-2045(15)00446-5","journal-title":"Lancet Oncol"},{"key":"7639_CR35","doi-asserted-by":"publisher","unstructured":"Schmitz RSJM et al (2023) Active surveillance versus treatment in low-risk DCIS; women\u2019s preferences in the LORD-trial. Eur J Cancer 192:113276. https:\/\/doi.org\/10.1016\/j.ejca.2023.113276","DOI":"10.1016\/j.ejca.2023.113276"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07639-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:02:13Z","timestamp":1743386533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7639"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07639-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests \/ personal relationships which may be considered as potential competing interests: BvdV reports honoraria received by UMCG for expertise or scientific advisory board\/consultancy (on request) for Visiopharm, Philips, MSD\/Merck, Daiichi-Sankyo\/AstraZenica; Speaker\u2019s fee from Visiopharm, Diaceutics, MSD\/Merck; Research grants from OWKIN and GE Healthcare; Personal fees from DEKRA. All honoraria to UMCG. All unrelated to the current manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study used publicly available anonymized data, thus was exempt from ethical compliance (IRB approval M24.331461, Medical Ethics Review Board Groningen, The Netherlands).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}